Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines

Richard T. Hoppe; Ranjana H. Advani; Weiyun Z. Ai; Richard F. Ambinder; Patricia Aoun; Celeste M. Bello; Philip J. Bierman; Kristie A. Blum; Robert Chen; Bouthaina Dabaja; Ysabel Duron; Andres Forero; Leo I. Gordon; Francisco J. Hernandez-Ilizaliturri; Ephraim P. Hochberg; David G. Maloney; David Mansur; Peter M. Mauch; Monika Metzger; Joseph O. Moore; David Morgan; Craig H. Moskowitz; Matthew Poppe; Barbara Pro; Jane N. Winter; Joachim Yahalom; Hema Sundar

doi:10.6004/jnccn.2012.0061

Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. MooreDavid Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Jane N. Winter, Joachim Yahalom, Hema Sundar

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

81 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.

Original language	English (US)
Pages (from-to)	589-597
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	10
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2012.0061
State	Published - May 1 2012

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2012.0061

Cite this

Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Duron, Y., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hochberg, E. P., Maloney, D. G., Mansur, D., Mauch, P. M., Metzger, M., ... Sundar, H. (2012). Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(5), 589-597. https://doi.org/10.6004/jnccn.2012.0061

Hoppe, RT, Advani, RH, Ai, WZ, Ambinder, RF, Aoun, P, Bello, CM, Bierman, PJ, Blum, KA, Chen, R, Dabaja, B, Duron, Y, Forero, A, Gordon, LI, Hernandez-Ilizaliturri, FJ, Hochberg, EP, Maloney, DG, Mansur, D, Mauch, PM, Metzger, M, Moore, JO, Morgan, D, Moskowitz, CH, Poppe, M, Pro, B, Winter, JN, Yahalom, J & Sundar, H 2012, 'Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 5, pp. 589-597. https://doi.org/10.6004/jnccn.2012.0061

@article{0925312e708c497eb19893ceb9e9de06,

title = "Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.",

author = "Hoppe, {Richard T.} and Advani, {Ranjana H.} and Ai, {Weiyun Z.} and Ambinder, {Richard F.} and Patricia Aoun and Bello, {Celeste M.} and Bierman, {Philip J.} and Blum, {Kristie A.} and Robert Chen and Bouthaina Dabaja and Ysabel Duron and Andres Forero and Gordon, {Leo I.} and Hernandez-Ilizaliturri, {Francisco J.} and Hochberg, {Ephraim P.} and Maloney, {David G.} and David Mansur and Mauch, {Peter M.} and Monika Metzger and Moore, {Joseph O.} and David Morgan and Moskowitz, {Craig H.} and Matthew Poppe and Barbara Pro and Winter, {Jane N.} and Joachim Yahalom and Hema Sundar",

year = "2012",

month = may,

day = "1",

doi = "10.6004/jnccn.2012.0061",

language = "English (US)",

volume = "10",

pages = "589--597",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

TY - JOUR

T1 - Hodgkin lymphoma, version 2.2012

T2 - Featured updates to the NCCN guidelines

AU - Hoppe, Richard T.

AU - Advani, Ranjana H.

AU - Ai, Weiyun Z.

AU - Ambinder, Richard F.

AU - Aoun, Patricia

AU - Bello, Celeste M.

AU - Bierman, Philip J.

AU - Blum, Kristie A.

AU - Chen, Robert

AU - Dabaja, Bouthaina

AU - Duron, Ysabel

AU - Forero, Andres

AU - Gordon, Leo I.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Hochberg, Ephraim P.

AU - Maloney, David G.

AU - Mansur, David

AU - Mauch, Peter M.

AU - Metzger, Monika

AU - Moore, Joseph O.

AU - Morgan, David

AU - Moskowitz, Craig H.

AU - Poppe, Matthew

AU - Pro, Barbara

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Sundar, Hema

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.

UR - http://www.scopus.com/inward/record.url?scp=84861813756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861813756&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0061

DO - 10.6004/jnccn.2012.0061

M3 - Review article

C2 - 22570290

AN - SCOPUS:84861813756

SN - 1540-1405

VL - 10

SP - 589

EP - 597

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this